AZ and Pieris link in $2.1bn respiratory deal
AstraZeneca has hooked up with US group Pieris Pharmaceuticals to develop novel inhaled medicines for respiratory diseases in a deal potentially worth $2.1 billion.
Read More
Tag: anticalin
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
